
Opella
French consumer healthcare company headquartered in Paris, created in April 2025 through the separation of Sanofi's consumer health business. Backed by Clayton, Dubilier & Rice, Opella reports approximately EUR 4.6 billion in annual revenue across a portfolio of about 100 OTC and self-care brands including Allegra and Dulcolax.
Company Type
private
Founded
2025
Headquarters
Paris, France
Revenue
approximately EUR 4.6 billion (FY2025)
Employees
more than 11,000
Primary Market
Global
Opella Timeline
Shop Opella Brands
Disclosure: We may earn commission from purchasesAbout Opella
Who owns Opella?
Opella is controlled by Clayton, Dubilier & Rice, the American private equity firm that acquired a majority stake when Sanofi separated its consumer health business in April 2025. Sanofi retained a minority shareholding in the new company.
Is Opella publicly traded?
No. Opella is a private company backed by Clayton, Dubilier & Rice and has no stock listing. Unlike rivals Haleon and Kenvue, which separated via public market spin-offs, Opella was created through a private equity transaction.
How many brands does Opella own?
Opella markets approximately 100 brands across consumer health categories, including Allegra, Dulcolax, Buscopan, Doliprane, Enterogermina, Gold Bond, Icy Hot, Essentiale, Mucosolvan, and Xyzal.
Where is Opella headquartered?
Opella is headquartered in Paris, France, reflecting its origin as Sanofi's consumer healthcare division. It operates directly in 38 countries and employs more than 11,000 people.
When was Opella founded?
Opella became an independent company in April 2025, when Sanofi completed the separation of its consumer health business into the CD&R-backed standalone company. The underlying business and brands are decades older.
What is Opella's revenue?
Opella reports approximately EUR 4.6 billion in annual revenue for fiscal year 2025. As a private company, it discloses limited financial detail compared with publicly listed consumer health peers.
History of Opella
Opella's history is the history of Sanofi's consumer health business. For decades the division operated as the over-the-counter and self-care arm of the French pharmaceutical group, building a portfolio of legacy brands including Doliprane, Dulcolax, Buscopan, and the allergy medicine Allegra.
Sanofi decided to separate the business as part of a strategic refocusing on innovative medicines and vaccines, announcing plans to divest consumer health and selecting Clayton, Dubilier & Rice as buyer of a controlling stake. The transaction completed in April 2025, formally creating Opella as an independent company headquartered in France.
The separation made Opella one of the largest standalone consumer health companies in the world from day one, with approximately 100 brands, more than 11,000 employees, and direct operations in 38 countries. It positioned the business alongside Haleon, Kenvue, and Bayer Consumer Health as a top-tier OTC player, but under private equity ownership rather than public listing.
In its first year and a half of independence through 2026, Opella focused on establishing its standalone identity, brand, and corporate infrastructure, reporting EUR 4.6 billion in FY2025 revenue and describing itself as a pure-play consumer healthcare company with global reach.
Opella Sustainability & Ethics
As a newly independent private company, Opella is still building formal ESG reporting infrastructure, and it holds no independent certifications such as B Corp. Its public commitments emphasize responsible self-care, access to medicines, and maintaining the quality standards inherited from its pharmaceutical heritage.
The company describes its mission around empowering self-care and supporting healthcare system sustainability through OTC products that reduce strain on professional care, a positioning statement rather than a certified sustainability claim.
Controversy, Regulation & Public Scrutiny
Opella's separation attracted political attention in France, where the sale of Sanofi's consumer health business to American private equity prompted debate over domestic ownership of a strategic healthcare asset and concerns about potential offshoring of production. The transaction proceeded in April 2025 with commitments around maintaining French operations and employment.
Beyond the separation politics, the company inherited the ordinary regulatory obligations of an OTC medicine maker, including product safety compliance across its markets. No major product safety scandal has been associated with the Opella portfolio through 2026.
Brands Owned by Opella
Opella owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Opella
private · Founded 2025 · Paris, France
1
brands
Opella Ownership: Pros & Cons
Advantages
- +Immediate scale with approximately EUR 4.6 billion in revenue and 100 brands
- +Pure-play consumer health focus, no longer competing with pharma R&D for capital
- +CD&R backing provides patient capital for brand investment and bolt-on deals
- +Established manufacturing, R&D, and distribution infrastructure inherited intact
- +Allegra and other flagship brands carry decades of consumer trust
Considerations
- -Private equity ownership typically implies an eventual exit through sale or IPO
- -Limited financial transparency compared with listed peers like Haleon and Kenvue
- -Political sensitivity in France over foreign control of a healthcare asset
- -Must build independent corporate functions after decades inside Sanofi
- -Faces giants in a competitive OTC market where scale drives pharmacy shelf share
Frequently Asked Questions About Opella
Who owns Opella?
Opella is controlled by Clayton, Dubilier & Rice, the American private equity firm that acquired a majority stake when Sanofi separated its consumer health business in April 2025. Sanofi retained a minority shareholding in the new company.
Is Opella publicly traded?
No. Opella is a private company backed by Clayton, Dubilier & Rice and has no stock listing. Unlike rivals Haleon and Kenvue, which separated via public market spin-offs, Opella was created through a private equity transaction.
How many brands does Opella own?
Opella markets approximately 100 brands across consumer health categories, including Allegra, Dulcolax, Buscopan, Doliprane, Enterogermina, Gold Bond, Icy Hot, Essentiale, Mucosolvan, and Xyzal.
Where is Opella headquartered?
Opella is headquartered in Paris, France, reflecting its origin as Sanofi's consumer healthcare division. It operates directly in 38 countries and employs more than 11,000 people.
When was Opella founded?
Opella became an independent company in April 2025, when Sanofi completed the separation of its consumer health business into the CD&R-backed standalone company. The underlying business and brands are decades older.
What is Opella's revenue?
Opella reports approximately EUR 4.6 billion in annual revenue for fiscal year 2025. As a private company, it discloses limited financial detail compared with publicly listed consumer health peers.








